GIP/GLP-1 Dual Agonists The research shows that tirzepatide outperforms semaglutide at both weight loss and blood sugar control
Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Kober LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probstfield JL, Riddle MC, Solomon SD, Tardif JC
10.1194/jlr.M075044 290
Abstract A suboptimal clinical response after metabolic and bariatric surgery (MBS) is common and carries considerable health concerns
Medical Expertise & Safety-First Approach Our board-certified medical professionals specialize in weight management and GLP-1 receptor agonists
In the LIVE trial of liraglutide in stable chronic HF, left ventricular function did not improve, heart rate increased, and serious cardiac adverse events were more frequent [47]